‘No therapeutics based upon new mechanisms-of-action have been approved for glaucoma in 15 years.D., CEO of Altheos.’ Related StoriesIRIDEX launches novel intra-ocular pressure monitoring deviceQuethera receives seed expenditure funding to develop gene therapy for glaucomaScientists elucidate genetic interaction that may prove key to advancement, progression of glaucomaAs part of the financing, Lester Kaplan, Ph.D., an associate of Bay City Capital’s scientific advisory plank and former President, Research and Development, and Board Member at Allergan, Inc. Will be joining the company’s board as Chairman. The plank will be further expanded to include Rob Hopfner of Bay Town Capital, Peter Bisgaard of Novo A/S and Wende Hutton of Canaan Partners.Medication mistakes include adverse drug reactions linked to prescribed or administered medications inappropriately. To minimize inappropriate medicine make use of, the U.S. Food and Medication Administration manuals pharmaceutical manufacturers and clinicians through drug labeling of which medications are contraindicated or not recommended for use in specific patient groupings, the authors write. Small is known about the use of such medications and their effects on outcomes in medical practice. Related StoriesPatients with kidney failing at increased risk of developing different types of cancerResearchers develop biophysical treatment method for dialysis patientsBoehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S.